ATE33938T1 - Herstellungsverfahren von zusammensetzungen mit kontrolliertem verabreichen biologisch aktiver materialien. - Google Patents

Herstellungsverfahren von zusammensetzungen mit kontrolliertem verabreichen biologisch aktiver materialien.

Info

Publication number
ATE33938T1
ATE33938T1 AT83903841T AT83903841T ATE33938T1 AT E33938 T1 ATE33938 T1 AT E33938T1 AT 83903841 T AT83903841 T AT 83903841T AT 83903841 T AT83903841 T AT 83903841T AT E33938 T1 ATE33938 T1 AT E33938T1
Authority
AT
Austria
Prior art keywords
compositions
manufacture
methods
biologically active
active materials
Prior art date
Application number
AT83903841T
Other languages
English (en)
Inventor
Sven Engstroem
Kare Larsson
Bjoern Lindman
Original Assignee
Fluidcrystal I Malmoe Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20348752&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE33938(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fluidcrystal I Malmoe Ab filed Critical Fluidcrystal I Malmoe Ab
Application granted granted Critical
Publication of ATE33938T1 publication Critical patent/ATE33938T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/829Liposomes, e.g. encapsulation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Fertilizers (AREA)
AT83903841T 1982-11-26 1983-11-25 Herstellungsverfahren von zusammensetzungen mit kontrolliertem verabreichen biologisch aktiver materialien. ATE33938T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE8206744A SE8206744D0 (sv) 1982-11-26 1982-11-26 Preparat for kontrollerad avgivning av substanser
PCT/SE1983/000411 WO1984002076A1 (en) 1982-11-26 1983-11-25 Method of preparing controlled-release preparations for biologically active materials and resulting compositions
EP83903841A EP0126751B2 (de) 1982-11-26 1983-11-25 Herstellungsverfahren von zusammensetzungen mit kontrolliertem verabreichen biologisch aktiver materialien

Publications (1)

Publication Number Publication Date
ATE33938T1 true ATE33938T1 (de) 1988-05-15

Family

ID=20348752

Family Applications (1)

Application Number Title Priority Date Filing Date
AT83903841T ATE33938T1 (de) 1982-11-26 1983-11-25 Herstellungsverfahren von zusammensetzungen mit kontrolliertem verabreichen biologisch aktiver materialien.

Country Status (11)

Country Link
US (2) US5151272A (de)
EP (1) EP0126751B2 (de)
JP (1) JPS60500256A (de)
AT (1) ATE33938T1 (de)
AU (2) AU2339684A (de)
DE (1) DE3376467D1 (de)
DK (1) DK166752B1 (de)
FI (1) FI83036C (de)
NO (1) NO173315C (de)
SE (1) SE8206744D0 (de)
WO (1) WO1984002076A1 (de)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8206744D0 (sv) * 1982-11-26 1982-11-26 Fluidcarbon International Ab Preparat for kontrollerad avgivning av substanser
IL79114A (en) * 1985-08-07 1990-09-17 Allergan Pharma Method and composition for making liposomes
CA1320130C (en) * 1986-06-12 1993-07-13 Alan L. Weiner Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
US5371109A (en) * 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
GB8906234D0 (en) * 1989-03-17 1989-05-04 Albright & Wilson Agrochemical suspensions
US5196201A (en) * 1989-10-20 1993-03-23 Bioapatite Ab Implant material composition, preparation thereof as well as uses thereof and implant product obtainable therefrom
US5143934A (en) * 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
FR2681781A1 (fr) 1991-09-30 1993-04-02 Oreal Composition cosmetique anhydre de maquillage comprenant une phase grasse et procede de traitement cosmetique utilisant cette composition.
WO1993006921A1 (en) * 1991-10-04 1993-04-15 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
ATE182278T1 (de) * 1991-10-04 1999-08-15 Gs Dev Ab Teilchen, methode zur herstellung der teilchen und deren verwendung
CA2082561A1 (en) * 1991-11-12 1993-05-13 Francis J. Leng Antiperspirant materials and compositions
SE9200951D0 (sv) * 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical composition containing a defined lipid system
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
ES2152329T3 (es) * 1993-08-18 2001-02-01 Alcon Lab Inc Composiciones derivadas de ergolina para el tratamiento del glaucoma.
SE9402455L (sv) * 1994-07-12 1996-01-13 Karlshamns Lipidteknik Ab Biskiktspreparat
SE518823C2 (sv) * 1994-07-12 2002-11-26 Karlshamns Lipidteknik Ab Olja-i-vatten-emulsioner
NZ279953A (en) * 1994-02-04 1998-02-26 Scotia Lipidteknik Ab Lipid-polar solvent bilayer carrier preparation (eg liposomes) comprising digalactosyldiacylglycerols as the bilayer material
SE517678C2 (sv) * 1994-07-12 2002-07-02 Lipocore Holding Ab Lipofila bärarpreparat med en kontinuerlig lipidfas
CN1098681C (zh) * 1994-02-04 2003-01-15 施科舍里皮技术有限公司 水包油乳液及其用途以及含有该水包油乳液的药用组合物
HU221432B (en) * 1994-02-04 2002-10-28 Lipocore Holding Ab Lipophilic carrier preparations
FR2720937B1 (fr) * 1994-06-08 1997-03-28 Oreal Composition cosmétique ou dermatologique sous forme de dispersion, aqueuse et stable, de particules de gel cubique à base de phytantriol et contenant un agent tensioactif à chaîne grasse en tant qu'agent dispersant et stabilisant.
SE518578C2 (sv) * 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
SE518619C2 (sv) * 1994-12-09 2002-10-29 Gs Dev Ab Komposition för reglerad frisättning innehållande monokaproin
FR2726762B1 (fr) * 1994-11-10 1997-01-17 Oreal Composition cosmetique ou dermatologique sous forme d'une dispersion d'une phase huileuse dans une phase aqueuse stabilisee a l'aide de particules de gel cubique et son procede d'obtention
FR2738565B1 (fr) * 1995-09-13 1997-11-28 Dior Christian Parfums Produits extraits d'une plante du genre commiphora, en particulier de la plante commiphora mukul, et extraits en contenant et leurs applications notamment en cosmetique
CO4910145A1 (es) * 1996-10-01 2000-04-24 Smithkline Beecham Corp Uso
PL332642A1 (en) * 1996-10-01 1999-09-27 Smithkline Beecham Corp Application of mupyrrocin in production of a drug for treating bacterial infections associated with invasion of nasopharynx by pathogenic organisms
NZ335676A (en) 1997-09-09 2001-03-30 Select Release L Coated particles comprising an exterior coating and a matrix comprising a liquid phase or liquid crystalline phase which is nanostructured
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
EP0948902A1 (de) * 1998-03-13 1999-10-13 Societe Des Produits Nestle S.A. Nahrungsmittel enthaltend eine mesomorphe Phase aus Monoglyceride
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
ATE280571T1 (de) 1999-08-06 2004-11-15 Max Delbrueck Centrum Implantierbares wirkstoffdepot
US6348215B1 (en) 1999-10-06 2002-02-19 The Research Foundation Of State University Of New York Stabilization of taxane-containing dispersed systems
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
US6465002B1 (en) 2000-03-13 2002-10-15 Brown University Research Foundation Liquid crystalline polymers
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
US6812205B2 (en) 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
US20020153508A1 (en) * 2000-06-29 2002-10-24 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
DE10057769A1 (de) * 2000-11-22 2002-05-23 Beiersdorf Ag Haarpflegeprodukte mit einem Gehalt an dispersen Flüssigkristallen, welche kubische Phasen darstellen
DE10057770A1 (de) * 2000-11-22 2002-05-23 Beiersdorf Ag Hautpflegeprodukte mit einem Gehalt an dispersen Flüssigkristallen, welche kubische Phasen darstellen ,
DE60129156T2 (de) * 2000-11-29 2008-03-13 Lyotropic Therapeutics, Inc. Lösungsmittelsysteme für pharmazeutische mittel
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6656385B2 (en) * 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
DE10127406A1 (de) * 2001-06-06 2002-12-12 Xzillion Gmbh & Co Kg Verfahren zur elektrophoretischen Trennung von Proben
WO2003039612A1 (en) * 2001-11-08 2003-05-15 Atrium Medical Corporation Intraluminal device with a coating containing a therapeutic agent
US20040022820A1 (en) * 2001-11-28 2004-02-05 David Anderson Reversed liquid crystalline phases with non-paraffin hydrophobes
AU2003231234A1 (en) * 2002-05-03 2003-11-17 Children's Hospital Medical Center Simulated vernix compositions for skin cleansing and other applications
US20040018237A1 (en) 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
DE10251963A1 (de) * 2002-11-08 2004-05-19 Lts Lohmann Therapie-Systeme Ag Transmucosale pharmazeutische Darreichungsform
US20050119340A1 (en) * 2003-06-13 2005-06-02 David Anderson Treatment methods with low-dose, longer-acting formulations of local anesthetics and other agents
WO2005021046A1 (en) * 2003-09-01 2005-03-10 Fh Faulding & Co Ltd Compositions and methods for delivery of biologically active agents
US7713440B2 (en) * 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
KR20050081092A (ko) * 2004-02-12 2005-08-18 한국과학기술연구원 생체적합성 친수성 고분자를 포함하는 콜로이드계 조성물,제형 및 이들의 제조 방법
SE0401942D0 (sv) * 2004-07-28 2004-07-28 Lipopeptide Ab New antimicrobial peptide complexes
EP1811933B1 (de) 2004-09-28 2016-03-23 Atrium Medical Corporation Barriereschicht
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
US20060067977A1 (en) * 2004-09-28 2006-03-30 Atrium Medical Corporation Pre-dried drug delivery coating for use with a stent
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US20060083768A1 (en) * 2004-09-28 2006-04-20 Atrium Medical Corporation Method of thickening a coating using a drug
US8535709B2 (en) * 2004-12-13 2013-09-17 Southeastern Medical Technologies, Llc Agents for controlling biological fluids and methods of use thereof
US20060127437A1 (en) * 2004-12-13 2006-06-15 Misty Anderson Kennedy Semisolid system and combination semisolid, multiparticulate system for sealing tissues and/or controlling biological fluids
US20070059350A1 (en) * 2004-12-13 2007-03-15 Kennedy John P Agents for controlling biological fluids and methods of use thereof
EP1835933A4 (de) 2005-01-04 2015-01-07 Yeda Res & Dev Hsp60, hsp60-peptide und t-zellen-impfstoffe zur immunmodulation
US7125954B2 (en) * 2005-01-27 2006-10-24 General Electric Company Method for producing polyether polymers
EP1874334A4 (de) * 2005-04-15 2011-03-30 Vascular Biogenics Ltd Zusammensetzungen mit von beta 2-glykoprotein i stammenden peptiden zur prävention und/oder behandlung von gefässerkrankungen
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
CA2626030A1 (en) 2005-10-15 2007-04-26 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
EP2083875B1 (de) 2006-11-06 2013-03-27 Atrium Medical Corporation Beschichtetes chirurgisches netz
CZ2006697A3 (cs) * 2006-11-07 2008-05-21 Zentiva, A. S. Kompozice depotních olanzapinových injekcních systému
EP2242478A2 (de) * 2008-01-02 2010-10-27 Kringle Pharma Inc. Topische zusammensetzungen zur verabreichung von proteinen und peptiden
EP2393472B1 (de) 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
WO2012009707A2 (en) 2010-07-16 2012-01-19 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
EP2685962A1 (de) 2011-03-17 2014-01-22 Transdermal Biotechnology, Inc. Topische stickoxidsysteme sowie verfahren zu ihrer verwendung
JP6081479B2 (ja) 2011-12-05 2017-02-15 カムルス エービー 頑強な徐放性ペプチド製剤
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
WO2014056939A1 (en) 2012-10-08 2014-04-17 Universität Zürich Lipidic biomaterials for encapsulation and triggered release
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US10722462B2 (en) 2014-12-10 2020-07-28 Council Of Scientific And Industrial Research Discontinuous reverse micellar composition in cubic FD3M phase for sustained release of therapeutic drugs
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
JP2021531348A (ja) 2018-07-20 2021-11-18 リポシン,インク. 肝臓病
EP4593839A1 (de) * 2022-09-26 2025-08-06 Universität Bern Strukturierte lipidzusammensetzungen

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4073943A (en) * 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US4115313A (en) * 1974-10-08 1978-09-19 Irving Lyon Bile acid emulsions
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4086257A (en) * 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
JPS5356315A (en) * 1976-11-01 1978-05-22 Eisai Co Ltd Emulsified solution of fat soluble drugs
JPS53107408A (en) * 1977-02-28 1978-09-19 Yamanouchi Pharmaceut Co Ltd Micellar preparation for rectal infusion
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS54122719A (en) * 1978-03-16 1979-09-22 Sankyo Co Ltd Carcinostatic agent for oral administration
US4377567A (en) * 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
US4241046A (en) * 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
IT1129711B (it) * 1980-01-23 1986-06-11 Montedison Spa Formulazioni solide contenenti ferormoni
US4342826A (en) * 1980-02-04 1982-08-03 Collaborative Research, Inc. Immunoassay products and methods
JPS609726B2 (ja) * 1980-05-15 1985-03-12 株式会社 ミドリ十字 ステロイド製剤
JPS574913A (en) * 1980-06-11 1982-01-11 Green Cross Corp:The Urokinase preparation for oral administration
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
JPS5775916A (en) * 1980-10-29 1982-05-12 Nippon Chemiphar Co Ltd Coenzyme q pharmaceutical and its preparation
JPS5793909A (en) * 1980-12-03 1982-06-11 Sankyo Co Ltd Carcinostatic pharmaceutical having directivity to specific internal organ and its preparation
JPS5716818A (en) * 1981-04-25 1982-01-28 Green Cross Corp:The Steroid fatty emulsion
SE8206744D0 (sv) * 1982-11-26 1982-11-26 Fluidcarbon International Ab Preparat for kontrollerad avgivning av substanser
US4789633A (en) * 1984-04-19 1988-12-06 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
US5143934A (en) * 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents
US5262164A (en) * 1989-11-17 1993-11-16 The Procter & Gamble Company Sustained release compositions for treating periodontal disease

Also Published As

Publication number Publication date
FI83036B (fi) 1991-02-15
DK362284D0 (da) 1984-07-24
NO173315C (no) 1993-12-01
WO1984002076A1 (en) 1984-06-07
FI842983A0 (fi) 1984-07-26
SE8206744D0 (sv) 1982-11-26
US5753259A (en) 1998-05-19
EP0126751A1 (de) 1984-12-05
DK362284A (da) 1984-07-24
AU615453B2 (en) 1991-10-03
NO173315B (no) 1993-08-23
EP0126751B2 (de) 1993-01-20
FI83036C (fi) 1991-05-27
AU2339684A (en) 1984-06-18
US5151272A (en) 1992-09-29
FI842983L (fi) 1984-07-26
DK166752B1 (da) 1993-07-12
DE3376467D1 (en) 1988-06-09
NO843023L (no) 1984-07-25
AU1819388A (en) 1988-10-27
EP0126751B1 (de) 1988-05-04
JPS60500256A (ja) 1985-02-28

Similar Documents

Publication Publication Date Title
ATE33938T1 (de) Herstellungsverfahren von zusammensetzungen mit kontrolliertem verabreichen biologisch aktiver materialien.
FI964959A0 (fi) Diasyyliglyserolia, fosfolipidiä, polaarista nestettä ja biologisesti aktiivista materiaalia sisältävä lipidipohjainen koostumus
DK0413171T3 (da) Middel til behandling af svære smertetilstande og fremgangsmåde til fremstilling heraf
ES8400870A1 (es) Un procedimiento para la preparacion de un articulo moldeado solido que comporta una cantidad unitaria predeterminada de un producto quimico.
ES8600060A1 (es) Procedimiento para preparar un medicamento envasado que contiene como sustancia activa un antagonista del calcio tal como nifedipina, verapamil diltiazem y otros.
ATE77740T1 (de) Verfahren zur herstellung von arzneimittelformulierungen mit gesteuerter und verlaengerter wirkung in einzeldosisform mit einheitlichen und vergleichbaren bioverfuegbarkeitscharakteristika.
DE3061586D1 (en) Pancreozymin-cholezystokinin active peptides, process for their preparation and pharmaceutical compositions containing them
SE8602931D0 (sv) A controlled-release composition
GB1461625A (en) Preparation of a composition containing a volatile substance
HU170896B (hu) Pesticidnye preparaty soderzhahhie aktivnye vehhestva tipa piretroida i sposob poluchenija aktivnykh vehhestv
EP0003833A3 (en) Antigen derivatives, process for their preparation, pharmaceutical compositions containing them, starting materials and their preparation
HU172213B (hu) Sposob poluchenija 16al'fa, 17al'fa-ciklopentilidendioksi-9al'fa-ftor-11beta, 21-digidroksi-pregna-1,4-dien-3,20-dion-21-acetata i lechebnykh preparatov soderzhahhikh ehto soedinenie kak aktivnyj komponent
FR2535969B1 (fr) Compose ether de polyol, son procede de preparation et composition cosmetique le contenant
FI800155A7 (fi) Kosmeettisina aineina käytettäviä seoksia ja menetelmä niiden aktiivisten aineosien valmistamiseksi.
IT1171477B (it) Derivati del 4h-1,2,4-triazolo procedimento per la loro preparazione, loro impiego in quanto farmaci, composizioni che li contengono e prodotti intermedi ottenuti
CA999820A (en) Method for preparation of insoluble biologically active materials
IL47268A (en) Racemic or optically active 4-acyl-1,3,4,5-tetrahydro-2h-1,4-benzo-diazepin-2-ones,process for their preparation and pharmaceutical compositions containing them
HUT34489A (en) Process for preparing 7-oxo-4-thia-1-aza-bicyclo/3,2,0/hept-2-ene derivatives and pharmaceutical compositions containing thereof as active substances
IL59842A0 (en) New biologically active substance obtained from cells of a new microorganism,a process for the preparation thereof and pharmaceutical compositions containing the same
DE2966607D1 (en) Medicines containing as active ingredients compounds of the benzene-sulfone type; compounds of this type and process for their preparation
JPS5241291A (en) Materials used for tissue culture
HUT34020A (en) Process for preparing new cyano-guanidine derivatives and pharmaceutical compositions containing such derivatives as active substances
JPS5226943A (en) Manufacturingmethod of structural member of footwear
GB1243454A (en) Pharmaceutical compositions and their preparation
JPS52130905A (en) Medicinal composition

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee